173 related articles for article (PubMed ID: 7533350)
21. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives.
Nalesnik MA
Semin Thorac Cardiovasc Surg; 1996 Apr; 8(2):139-48. PubMed ID: 8672567
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases.
Hauke RJ; Greiner TC; Smir BN; Vose JM; Tarantolo SR; Bashir RM; Bierman PJ
Bone Marrow Transplant; 1998 Jun; 21(12):1271-4. PubMed ID: 9674863
[TBL] [Abstract][Full Text] [Related]
23. Therapy for transplant-related lymphoproliferative diseases.
Benkerrou M; Durandy A; Fischer A
Hematol Oncol Clin North Am; 1993 Apr; 7(2):467-75. PubMed ID: 8385662
[TBL] [Abstract][Full Text] [Related]
24. Immunologic disorders in posttransplant lymphoma: therapeutic implications.
Jacobs U; Niese D; Brensing KA; Eis-Hübinger A; Buszello H; Klehr HU
Transplant Proc; 1996 Dec; 28(6):3249-50. PubMed ID: 8962259
[No Abstract] [Full Text] [Related]
25. [Clinical aspects of Epstein-Barr-virus-associated lymphoproliferative disease].
Kvell K; Balogh P; Németh P
Orv Hetil; 2002 Apr; 143(14):713-9. PubMed ID: 11975391
[TBL] [Abstract][Full Text] [Related]
26. Duration of Epstein-Barr virus (EBV)-associated polyclonal lymphoproliferative disease (LPD) following bone marrow transplantation.
Imashuku S; Iwami H; Tsunamoto K; Hibi S; Todo S
Bone Marrow Transplant; 1996 Oct; 18(4):823-4. PubMed ID: 8899207
[No Abstract] [Full Text] [Related]
27. [Opportunistic lymphoma].
Katano H; Mori S
Nihon Rinsho; 1997 Feb; 55(2):441-5. PubMed ID: 9046838
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation for Epstein-Barr virus-related clonal T cell proliferation associated with hemophagocytosis.
Imashuku S; Naya M; Yamori M; Nakabayashi Y; Hojo M; Kihara A; Tabata Y; Akioka C; Hibi S; Todo S
Bone Marrow Transplant; 1997 May; 19(10):1059-60. PubMed ID: 9169655
[No Abstract] [Full Text] [Related]
29. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
[TBL] [Abstract][Full Text] [Related]
30. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
[TBL] [Abstract][Full Text] [Related]
31. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis.
Kuo PC; Dafoe DC; Alfrey EJ; Sibley RK; Scandling JD
Transplantation; 1995 Jan; 59(1):135-8. PubMed ID: 7839414
[No Abstract] [Full Text] [Related]
32. Epstein-Barr virus (EBV)-associated hepatic and splenic smooth muscle tumours after kidney transplantation.
Morel D; Merville P; Le Bail B; Berger F; Saric J; Potaux L
Nephrol Dial Transplant; 1996 Sep; 11(9):1864-6. PubMed ID: 8918643
[No Abstract] [Full Text] [Related]
33. Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression.
Lelièvre JD; Sacre K; Adle-Biassette H; Molinier-Frenkel V; Gaulard P; Papo T
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):24-7. PubMed ID: 15692507
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.
Nalesnik MA; Starzl TE
Transplant Sci; 1994 Sep; 4(1):61-79. PubMed ID: 7804700
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus and bone marrow transplantation.
Caldas C; Ambinder R
Curr Opin Oncol; 1995 Mar; 7(2):102-6. PubMed ID: 7756374
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients.
Sokal EM; Caragiozoglou T; Lamy M; Reding R; Otte JB
Transplantation; 1993 Dec; 56(6):1394-8. PubMed ID: 8279009
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease.
Perera SM; Thomas JA; Burke M; Crawford DH
J Pathol; 1998 Feb; 184(2):177-84. PubMed ID: 9602709
[TBL] [Abstract][Full Text] [Related]
39. Therapy of transplant-related lymphoproliferative diseases.
Benkerrou M; Durandy A; Brousse N; Fischer A
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):55-9. PubMed ID: 8390048
[No Abstract] [Full Text] [Related]
40. Molecular genetic analysis of post-transplant lymphoproliferative disorders.
Seiden MV; Sklar J
Hematol Oncol Clin North Am; 1993 Apr; 7(2):447-65. PubMed ID: 8385661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
